Abstract Cyclosporine (CsA), an oral calcineurin inhibitor, is frequently used off‐label in paediatric dermatology to manage severe inflammatory skin conditions rapidly. The current literature on this topic encompasses various sources, including systematic reviews, meta‐analyses, case series, narrative reviews and clinical trials, with a focus on atopic dermatitis, chronic urticaria, drug reaction with eosinophilia and systemic symptoms (DReSS), Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), reactive infectious mucocutaneous eruption (RIME) and psoriasis. While some studies include adult data, they support the use of CsA as a viable treatment option in well‐selected paediatric patients when accompanied by diligent monitoring. This review highlights common dosing strategies, typically weight‐based and reports consistent rapid clinical improvement and steroid‐sparing effects. Although adverse events may occur, they are generally reversible; however, careful monitoring is recommended.
Pozzo‐Magaña et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: